CA3235913A1 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof - Google Patents

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Download PDF

Info

Publication number
CA3235913A1
CA3235913A1 CA3235913A CA3235913A CA3235913A1 CA 3235913 A1 CA3235913 A1 CA 3235913A1 CA 3235913 A CA3235913 A CA 3235913A CA 3235913 A CA3235913 A CA 3235913A CA 3235913 A1 CA3235913 A1 CA 3235913A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
inhibitors
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235913A
Other languages
English (en)
French (fr)
Inventor
John BUELL
Frederick Cohen
Ryan PEMBERTON
Hunter P. Shunatona
Lan Wang
Mark Edward Zak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Nurix Therapeutics Inc
Original Assignee
Gilead Sciences Inc
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Nurix Therapeutics Inc filed Critical Gilead Sciences Inc
Publication of CA3235913A1 publication Critical patent/CA3235913A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3235913A 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Pending CA3235913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
US63/263,875 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
CA3235913A1 true CA3235913A1 (en) 2023-05-19

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235913A Pending CA3235913A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Country Status (12)

Country Link
US (2) US12091426B2 (cg-RX-API-DMAC7.html)
EP (1) EP4430052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543377A (cg-RX-API-DMAC7.html)
KR (1) KR20240101654A (cg-RX-API-DMAC7.html)
CN (1) CN118510786A (cg-RX-API-DMAC7.html)
AR (1) AR127625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022388571A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235913A1 (cg-RX-API-DMAC7.html)
IL (1) IL312361A (cg-RX-API-DMAC7.html)
MX (1) MX2024005431A (cg-RX-API-DMAC7.html)
TW (1) TW202334170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
EP3873608A1 (en) * 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN114423463B (zh) * 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
TWI918648B (zh) * 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途

Also Published As

Publication number Publication date
US20240018162A1 (en) 2024-01-18
IL312361A (en) 2024-06-01
WO2023086399A1 (en) 2023-05-19
US20240400587A1 (en) 2024-12-05
KR20240101654A (ko) 2024-07-02
MX2024005431A (es) 2024-07-19
JP2024543377A (ja) 2024-11-21
EP4430052A1 (en) 2024-09-18
AU2022388571A1 (en) 2024-05-09
AR127625A1 (es) 2024-02-14
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
CN118510786A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
AU2020368542B2 (en) Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety
US11739101B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
AU2019262927B2 (en) Pyridazinones as PARP7 inhibitors
CA3214806A1 (en) Modulators of bcl6 proteolysis and associated methods of use
ES2536281T3 (es) Antagonistas del receptor CXCR4
AU2010210019B2 (en) Compounds and compositions as protein kinase inhibitors
EP4367118B1 (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
KR20200101956A (ko) 6-아자인돌 화합물
KR20230117577A (ko) Brm을 표적으로 하는 화합물 및 연관된 사용 방법
JP2022531801A (ja) フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
US12091426B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
EP4342892A1 (en) Bruton's tyrosine kinase and mutant degrader, composition and application thereof
JP2022532145A (ja) 置換ベンズイミダゾロン化合物
WO2025019585A1 (en) Kinase inhibitors
CN121752567A (zh) 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物
HK40115438A (en) Bifunctional degradation agents of hematopoietic progenitor cell kinases and therapeutic uses thereof
HK40121612A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
HK40108095A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
HK40108095B (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
CN120957981A (zh) 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241101

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251031